1 Department of Blood Transfusion, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
J Intensive Care Med. 2018 May;33(5):296-309. doi: 10.1177/0885066616671710. Epub 2016 Oct 22.
INTRODUCTION: The Surviving Sepsis Campaign guidelines recommend early goal-directed therapy (EGDT) for the resuscitation of patients with sepsis; however, the recent evidences quickly evolve and convey conflicting results. We performed a meta-analysis to evaluate the effect of EGDT on mortality in adults with severe sepsis and septic shock. METHODS: We searched electronic databases to identify randomized controlled trials that compared EGDT with usual care or lactate-guided therapy in adults with severe sepsis and septic shock. Predefined primary outcome was all-cause mortality at final follow-up. RESULTS: We included 13 trials enrolling 5268 patients. Compared with usual care, EGDT was associated with decreased mortality (risk ratio [RR]: 0.87, 95% CI: 0.77-0.98; 4664 patients, 8 trials; Grading of Recommendations Assessment, Development, and Evaluation [GRADE] quality of evidence was moderate). Compared with lactate clearance-guided therapy, EGDT was associated with increased mortality (RR: 1.60, 95% CI: 1.24-2.06; 604 patients, 5 trials; GRADE quality of evidence was low). Patients assigned to EGDT received more intravenous fluid, red cell transfusion, vasopressor infusion, and dobutamine use within the first 6 hours than those assigned to usual care (all P values < .00001). CONCLUSION: Adults with severe sepsis and septic shock who received EGDT had a lower mortality than those given usual care, the benefit may mainly be attributed to treatments administered within the first 6 hours. However, the underlying mechanisms by which lactate clearance-guided therapy benefits these patients are yet to be investigated.
简介:《拯救脓毒症运动指南》建议对脓毒症患者进行早期目标导向治疗(EGDT);然而,新的证据不断涌现,结果相互矛盾。我们进行了一项荟萃分析,以评估 EGDT 对严重脓毒症和感染性休克成人患者死亡率的影响。
方法:我们检索电子数据库,以确定比较 EGDT 与常规治疗或乳酸指导治疗在严重脓毒症和感染性休克成人患者中的随机对照试验。预先定义的主要结局是最终随访时的全因死亡率。
结果:我们纳入了 13 项试验,共纳入 5268 名患者。与常规治疗相比,EGDT 降低了死亡率(风险比 [RR]:0.87,95%可信区间:0.77-0.98;4664 名患者,8 项试验;推荐分级评估、制定与评价 [GRADE] 证据质量为中级)。与乳酸清除指导治疗相比,EGDT 增加了死亡率(RR:1.60,95%可信区间:1.24-2.06;604 名患者,5 项试验;GRADE 证据质量为低)。与接受常规治疗的患者相比,接受 EGDT 的患者在最初 6 小时内接受了更多的静脉输液、红细胞输注、血管加压素输注和多巴酚丁胺使用(所有 P 值均<0.00001)。
结论:与常规治疗相比,接受 EGDT 的严重脓毒症和感染性休克患者死亡率较低,这一益处可能主要归因于在前 6 小时内进行的治疗。然而,乳酸清除指导治疗对这些患者有益的潜在机制仍有待研究。
Scand J Trauma Resusc Emerg Med. 2016-3-5
Curr Med Res Opin. 2016-11
Am J Transl Res. 2025-4-15
Medicine (Baltimore). 2024-11-29
BMC Infect Dis. 2023-5-22
J Pediatr Intensive Care. 2022-2-18
World J Gastroenterol. 2019-7-28